Mazer, C. David

One-Year Outcomes in Survivors of the Acute Respiratory Distress Syndrome

Herridge, M. S., Cheung, A. M., Tansey, C. M., Matte-Martyn, A., Diaz-Granados, N., Al-Saidi, F., Cooper, A. B., Guest, C. B., Mazer, C. D., Mehta, S., et al. (2003) · New England Journal of Medicine

Respiratory Support and MechanismsIntensive Care Unit Cognitive Disorders

Cited by 2,334

Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease

Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation

Erythropoietin and Anemia TreatmentDiabetes Treatment and Management

Cited by 371

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME

Verma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation

Diabetes Treatment and ManagementPeripheral Artery Disease Management

Cited by 166

Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery: A Randomized Clinical Study

Thielmann, M., Corteville, D., Szabo, G., Swaminathan, M., Lamy, A., Lehner, L. J., Brown, C. D., Noiseux, N., Atta, M. G., Squiers, E. C., et al. (2021) · Circulation

Acute Kidney Injury ResearchChronic Kidney Disease and Diabetes

Cited by 97

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

Verma, S., Al‐Omran, M., Leiter, L. A., Mazer, C. D., Rasmussen, S., Saevereid, H. A., Sejersten Ripa, M., & Bonaca, M. P. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPeripheral Artery Disease Management

Cited by 61

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 45

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use: Results From the LEADER Trial

Verma, S., Leiter, L. A., Mazer, C. D., Bain, S. C., Buse, J., Marso, S., Nauck, M., Zinman, B., Bosch-Traberg, H., Rasmussen, S., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35

Functional and anatomical evidence of cerebral tissue hypoxia in young sickle cell anemia mice

Cahill, L. S., Gazdzinski, L. M., Tsui, A. K., Zhou, Y.-Q., Portnoy, S., Liu, E., Mazer, C. D., Hare, G. M., Kassner, A., & Sled, J. G. (2017) · Journal of Cerebral Blood Flow & Metabolism

Hemoglobinopathies and Related DisordersBlood properties and coagulation

Cited by 26